Cytokinetics initiates trial of aficamten to treat nHCM

Cytokinetics has initiated a Phase III clinical trial of aficamten for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM).

Enrolment is open for the Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM (ACACIA-HCM) study.